What if your cancer didn’t begin as bad luck in your DNA — but was fueled by hidden infections your doctors never tested for?

In this episode of Outsmart Cancer, Dr. Dino Prato explains how chronic, undiagnosed infections can weaken the immune system, drive inflammation, disrupt tumor-suppressor pathways, and make cancer more aggressive and resistant to treatment.

While global estimates suggest about 13% of cancers are linked to infections, Dr. Prato’s clinical experience over more than 25 years shows the number may be far higher — largely because most patients are never thoroughly tested. Viruses, bacteria, parasites, mold toxins, and tick-borne infections can persist silently in the body, suppressing immunity long before cancer develops.

Dr. Prato breaks down the three primary ways infections contribute to cancer: direct oncogenic interference with tumor-suppressor genes like p53, genomic instability caused by viral integration, and chronic inflammation that fuels tumor growth and immune exhaustion. He also explains how infections disrupt mitochondrial signaling, impair natural killer cell function, and interfere with modern treatments — including immunotherapy.

This episode highlights why eliminating infections and restoring immune function must be part of precision oncology. Without addressing these hidden drivers, even the most advanced cancer therapies may fail to reach their full effectiveness.

🎯 What You’ll Learn in This Episode:

• Why infections are an overlooked contributor to cancer
• How viruses like HPV, EBV, and hepatitis affect tumor-suppressor genes
• The role of chronic inflammation and immune exhaustion
• Why infections increase treatment resistance and immune evasion
• How mitochondrial dysfunction impacts cancer immunity
• Why deep infectious disease testing is essential
• How eliminating infections can improve treatment response
  
  

📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: www.envita.com
📞 Speak with a care coordinator: 866-830-4576

“Cancer treatment works best when the immune system is no longer under attack.”

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493

If you’ve been told you have a KRAS mutation — or another so-called “undruggable” cancer gene — you may have been placed on a specialty inhibitor designed to slow the disease. And these drugs can be helpful. But there’s a critical truth most patients are never told:

Most targeted cancer drugs are cytostatic, not cytotoxic.
They slow cancer down — they don’t eliminate it.

In this episode of Outsmart Cancer, Dr. Dino Prato explains why drugs targeting KRAS, BRAF, EGFR, MET, HER2, and similar pathways often create a temporary “honeymoon period.” Like unplugging a Christmas tree, the tumors dim — but once the drug stops working, the cancer lights back up.

The key question becomes: What are you doing with the time these drugs buy you?

Dr. Prato walks through how precision oncology uses that window to activate the immune system. By combining full DNA sequencing, RNA transcriptomics, immune spatial biology, and deep pathway mapping, doctors can identify thousands of targets — not just one mutation. This allows precision combinations, off-label strategies, phytotherapeutics, and direct-to-tumor immunotherapy delivery to expose cancer antigens, release DAMPS, and train natural killer and dendritic cells to eliminate disease system-wide.

Instead of waiting for resistance, this approach turns cytostatic slowdown into cytotoxic immune control, even in patients labeled MSS or “not candidates” for standard immunotherapy.

🎯 What You’ll Learn in This Episode:
• Why KRAS and similar inhibitors slow cancer but rarely eliminate it
• The difference between cytostatic and cytotoxic cancer treatment
• Why specialty drugs create a critical treatment window
• How RNA transcriptomics reveals escape pathways beyond DNA mutations
• Why immune spatial biology is essential for durable response
• How direct-to-tumor delivery protects immunity and increases effectiveness
• Why PD-1 inhibitors alone are rarely enough
• The right questions to ask when your targeted drug stops working

📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: www.envita.com
📞 Speak with a care coordinator: 866-830-4576

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493

Something most cancer patients are never told:
the radiation plan you receive is often influenced by the machine a hospital owns, not by what’s best for your cancer biology.

Dr. Dino Prato breaks down the radiation wars — and introduces a disruptive technology that may change oncology entirely: ultrasound-based tumor destruction. Data shows that 40–50% of radiation therapy is palliative, meaning it’s designed to slow disease or reduce symptoms rather than eliminate cancer. The real question becomes: what are we doing during that time?

Dr. Prato explains why radiation has long been an adjuvant tool, how hospital economics and reimbursement drive its overuse, and why newer technologies often struggle to gain adoption. He then introduces histotripsy and sonodynamic therapy, which use focused sound waves to “melt” tumors without radiation. This process creates a tumor lysate rich in antigens, neoantigens, and DAMPS — powerful immune signals that can be repurposed into systemic immunotherapy.

Using precision oncology principles — DNA sequencing, RNA transcriptomics, immune profiling, spatial biology, and AI-guided analysis — this lysate can be combined with immunotherapy, phytotherapeutic adjuvants, and nanoparticle delivery to stimulate whole-body immune response, not just local tumor control.

This episode explores why ultrasound-based approaches may replace large portions of radiation oncology in the future, why adoption is slow, and how immune-centric precision care shifts cancer treatment from palliative delay to strategic immune activation.

🎯 What You’ll Learn in This Episode:
• Why 40–50% of radiation therapy is palliative
• How hospital ownership influences radiation decisions
• The difference between radiation destruction and immune training
• What histotripsy and sonodynamic therapy are
• How tumor lysate becomes immunotherapy
• Why ultrasound avoids many radiation side effects
• How precision oncology integrates sound, data, and immunity
• Why disruptive cancer technology takes years to reach patients

📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: www.envita.com
📞 Speak with a care coordinator: 866-830-4576

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493